Histone deacetylase inhibitors promote eNOS expression in vascular smooth muscle cells and suppress hypoxia-induced cell growth

Journal of Cellular and Molecular Medicine

Volumn 21, Issue 9, 2017, Pages 2022-2035

  Tan, Xiaoling ^a   Feng, Lan ^a   Huang, Xiaoyong ^a   Yang, Yidong ^a   Yang, Chengzhong ^a   Gao, Yuqi ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

endothelial nitric oxide synthase; histone deacetylase inhibitor; hypoxia; vascular remodelling; vascular smooth muscle cell

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA ACTIN; BUTYRIC ACID; CASPASE 3; COLLAGEN; CYCLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROTEIN P21; SMALL INTERFERING RNA; VORINOSTAT; 1,3-DIHYDROXY-4,4,5,5-TETRAMETHYL-2-(4-CARBOXYPHENYL)TETRAHYDROIMIDAZOLE; BENZOIC ACID DERIVATIVE; BUTYRIC ACID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; IMIDAZOLE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD OXYGEN TENSION; CELL ADHESION; CELL CYCLE ASSAY; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; HYPOXIA; IMMUNOFLUORESCENCE TEST; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE CELL; WESTERN BLOTTING; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL HYPOXIA; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOLOGY; PULMONARY ARTERY; SMOOTH MUSCLE CELL; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE; WISTAR RAT;

ANIMALS; APOPTOSIS; BENZOATES; BUTYRATES; CELL HYPOXIA; CELL PROLIFERATION; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; HYPOXIA; IMIDAZOLES; MALE; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PULMONARY ARTERY; RATS, WISTAR; VASCULAR REMODELING;

EID: 85014643372     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.13122     Document Type: Article

References (69)

1. Hanze J, Weissmann N, Grimminger F, et al. Cellular and molecular mechanisms of hypoxia-inducible factor driven vascular remodeling. Thromb Haemost. 2007; 97: 774–87.
2. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther. 2001; 92: 1–20.
3. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006; 99: 675–91.
4. Chen JS, Faller DV, Spanjaard RA. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr Cancer Drug Targets. 2003; 3: 219–36.
5. Shankar S, Srivastava RK. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol. 2008; 615: 261–98.
6. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012; 6: 637–56.
7. Cantoni S, Galletti M, Zambelli F, et al. Sodium butyrate inhibits platelet-derived growth factor-induced proliferation and migration in pulmonary artery smooth muscle cells through Akt inhibition. FEBS J. 2013; 280: 2042–55.
8. Findeisen HM, Gizard F, Zhao Y, et al. Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition. Arterioscler Thromb Vasc Biol. 2011; 31: 851–60.
9. Chen S, Sang N. Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol. 2011; 2011: 197946–59.
10. Ranganna K, Yousefipour Z, Yatsu FM, et al. Gene expression profile of butyrate-inhibited vascular smooth muscle cell proliferation. Mol Cell Biochem. 2003; 254: 21–36.
11. Feng P, Ge L, Akyhani N, et al. Sodium butyrate is a potent modulator of smooth muscle cell proliferation and gene expression. Cell Prolif. 1996; 29: 231–41.
12. Mathew OP, Ranganna K, Milton SG. Involvement of the antioxidant effect and anti-inflammatory response in butyrate-inhibited vascular smooth muscle cell proliferation. Pharmaceuticals (Basel). 2014; 7: 1008–27.
13. Mathew OP, Ranganna K, Yatsu FM. Butyrate, an HDAC inhibitor, stimulates interplay between different posttranslational modifications of histone H3 and differently alters G1-specific cell cycle proteins in vascular smooth muscle cells. Biomed Pharmacother. 2010; 64: 733–40.
14. Okamoto H, Fujioka Y, Takahashi A, et al. Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1). J Atheroscler Thromb. 2006; 13: 183–91.
15. Fish JE, Matouk CC, Rachlis A, et al. The expression of endothelial nitric-oxide synthase is controlled by a cell-specific histone code. J Biol Chem. 2005; 280: 24824–38.
16. Gan Y, Shen YH, Wang J, et al. Role of histone deacetylation in cell-specific expression of endothelial nitric-oxide synthase. J Biol Chem. 2005; 280: 16467–75.
17. Rossig L, Li H, Fisslthaler B, et al. Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res. 2002; 91: 837–44.
18. Chen HI, Chang HR, Wu CY, et al. Nitric oxide in the cardiovascular and pulmonary circulation–a brief review of literatures and historical landmarks. Chin J Physiol. 2007; 50: 43–50.
19. Crosswhite P, Sun Z. Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens. 2010; 28: 201–12.
20. Ho JJ, Man HS, Marsden PA. Nitric oxide signaling in hypoxia. J Mol Med (Berl). 2012; 90: 217–31.
21. Hubloue I, Biarent DAbdel Kafi S, et al. Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction. Eur Respir J. 2003; 21: 19–24.
22. Le Cras TD, McMurtry IF. Nitric oxide production in the hypoxic lung. Am J Physiol Lung Cell Mol Physiol. 2001; 280: L575–82.
23. Napoli C, Loscalzo J. Nitric oxide and other novel therapies for pulmonary hypertension. J Cardiovasc Pharmacol Ther. 2004; 9: 1–8.
24. De Pascali F, Hemann C, Samons K, et al. Hypoxia and reoxygenation induce endothelial nitric oxide synthase uncoupling in endothelial cells through tetrahydrobiopterin depletion and S-glutathionylation. Biochemistry. 2014; 53: 3679–88.
25. Rochette L, Lorin J, Zeller M, et al. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol Ther. 2013; 140: 239–57.
26. Sato J, Nair K, Hiddinga J, et al. eNOS gene transfer to vascular smooth muscle cells inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis. Cardiovasc Res. 2000; 47: 697–706.
27. Sharma RV, Tan E, Fang S, et al. NOS gene transfer inhibits expression of cell cycle regulatory molecules in vascular smooth muscle cells. Am J Physiol. 1999; 276: H1450–9.
28. Stotz WH, Li D, Johns RA. Exogenous nitric oxide upregulates p21(waf1/cip1) in pulmonary microvascular smooth muscle cells. J Vasc Res. 2004; 41: 211–9.
29. Hou X, Chen J, Luo Y, et al. Silencing of STIM1 attenuates hypoxia-induced PASMCs proliferation via inhibition of the SOC/Ca2+/NFAT pathway. Respir Res. 2013; 14: 2–11.
30. Ray JB, Arab S, Deng Y, et al. Oxygen regulation of arterial smooth muscle cell proliferation and survival. Am J Physiol Heart Circ Physiol. 2008; 294: H839–52.
31. Lv G, Li Y, Wang Z, et al. Hypoxia stimulates the proliferation of neonatal rat vascular smooth muscle cells through activation of hypoxia-inducible factor-1alpha. Int J Clin Exp Med. 2015; 8: 496–503.
32. Ranganna K, Joshi T, Yatsu FM. Sodium butyrate inhibits platelet-derived growth factor-induced proliferation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1995; 15: 2273–83.
33. Ranganna K, Yatsu FM. Inhibition of platelet-derived growth factor BB-induced expression of glyceraldehyde-3-phosphate dehydrogenase by sodium butyrate in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997; 17: 3420–7.
34. Ranganna K, Yatsu FM, Hayes BE, et al. Butyrate inhibits proliferation-induced proliferating cell nuclear antigen expression (PCNA) in rat vascular smooth muscle cells. Mol Cell Biochem. 2000; 205: 149–61.
35. Patel P, Nankova BB, LaGamma EF. Butyrate, a gut-derived environmental signal, regulates tyrosine hydroxylase gene expression via a novel promoter element. Brain Res Dev Brain Res. 2005; 160: 53–62.
36. Ranganna K, Mathew OP, Yatsu FM, et al. Involvement of glutathione/glutathione S-transferase antioxidant system in butyrate-inhibited vascular smooth muscle cell proliferation. FEBS J. 2007; 274: 5962–78.
37. Safaya S, Klings ES, Odhiambo A, et al. Effect of sodium butyrate on lung vascular TNFSF15 (TL1A) expression: differential expression patterns in pulmonary artery and microvascular endothelial cells. Cytokine. 2009; 46: 72–8.
38. Zapolska-Downar D, Siennicka A, Kaczmarczyk M, et al. Butyrate inhibits cytokine-induced VCAM-1 and ICAM-1 expression in cultured endothelial cells: the role of NF-kappaB and PPARalpha. J Nutr Biochem. 2004; 15: 220–8.
39. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis. 2002; 45: 173–202.
40. Milton SG, Mathew OP, Yatsu FM, et al. Differential cellular and molecular effects of butyrate and trichostatin a on vascular smooth muscle cells. Pharmaceuticals (Basel). 2012; 5: 925–43.
41. Song S, Kang SW, Choi C. Trichostatin A enhances proliferation and migration of vascular smooth muscle cells by downregulating thioredoxin 1. Cardiovasc Res. 2010; 85: 241–9.
42. Yang Q, Lu Z, Ramchandran R, et al. Pulmonary artery smooth muscle cell proliferation and migration in fetal lambs acclimatized to high-altitude long-term hypoxia: role of histone acetylation. Am J Physiol Lung Cell Mol Physiol. 2012; 303: L1001–10.
43. Dashwood RH, Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol. 2007; 17: 363–9.
44. Licciardi PV, Ververis K, Karagiannis TC. Histone deacetylase inhibition and dietary short-chain Fatty acids. ISRN Allergy. 2011; 2011: 869647–54.
45. Myzak MC, Ho E, Dashwood RH. Dietary agents as histone deacetylase inhibitors. Mol Carcinog. 2006; 45: 443–6.
46. Pham TX, Lee J. Dietary regulation of histone acetylases and deacetylases for the prevention of metabolic diseases. Nutrients. 2012; 4: 1868–86.
47. Steliou K, Boosalis MS, Perrine SP, et al. Butyrate histone deacetylase inhibitors. Biores Open Access. 2012; 1: 192–8.
48. Vinolo MA, Rodrigues HG, Nachbar RT, et al. Regulation of inflammation by short chain fatty acids. Nutrients. 2011; 3: 858–76.
49. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003; 9: 3578–88.
50. Wang Z, Chen C, Finger SN, et al. Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? Eur Respir J. 2009; 34: 145–55.
51. Felice C, Lewis A, Armuzzi A, et al. Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015; 41: 26–38.
52. Khan S, Jena G. Sodium butyrate, a HDAC inhibitor ameliorates eNOS, iNOS and TGF-beta1-induced fibrogenesis, apoptosis and DNA damage in the kidney of juvenile diabetic rats. Food Chem Toxicol. 2014; 73: 127–39.
53. Wang W, Yan M, Ji Q, et al. Suberoylanilide hydroxamic acid suppresses hepatic stellate cells activation by HMGB1 dependent reduction of NF-kappaB1. PeerJ. 2015; 3: e1362–75.
54. Sluiter I, van Heijst A, Haasdijk R, et al. Reversal of pulmonary vascular remodeling in pulmonary hypertensive rats. Exp Mol Pathol. 2012; 93: 66–73.
55. Church AC, Martin DH, Wadsworth R, et al. The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2015; 309: L333–47.
56. Schultz K, Fanburg BL, Beasley D. Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2006; 290: H2528–34.
57. Tajsic T, Morrell NW. Smooth muscle cell hypertrophy, proliferation, migration and apoptosis in pulmonary hypertension. Compr Physiol. 2011; 1: 295–317.
58. Cai Y, Han M, Luo L, et al. Increased expression of PDGF and c-myc genes in lungs and pulmonary arteries of pulmonary hypertensive rats induced by hypoxia. Chin Med Sci J. 1996; 11: 152–6.
59. Chanakira A, Dutta R, Charboneau R, et al. Hypoxia differentially regulates arterial and venous smooth muscle cell proliferation via PDGFR-beta and VEGFR-2 expression. Am J Physiol Heart Circ Physiol. 2012; 302: H1173–84.
60. Dahal BK, Heuchel R, Pullamsetti SS, et al. Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-beta. Pulm Circ. 2011; 1: 259–68.
61. ten Freyhaus H, Dagnell M, Leuchs M, et al. Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. Am J Respir Crit Care Med. 2011; 183: 1092–102.
62. Zhang L, Ma J, Shen T, et al. Platelet-derived growth factor (PDGF) induces pulmonary vascular remodeling through 15-LO/15-HETE pathway under hypoxic condition. Cell Signal. 2012; 24: 1931–9.
63. Ambalavanan N, Bulger A, Philips IJ. Hypoxia-induced release of peptide growth factors from neonatal porcine pulmonary artery smooth muscle cells. Biol Neonate. 1999; 76: 311–9.
64. Li F, Zhang Y, Che D. Platelet-derived growth factor (PDGF) mRNA expression of porcine pulmonary artery smooth muscle cells induced by hypoxic endothelial cells conditioned medium. Zhonghua Bing Li Xue Za Zhi. 1998; 27: 425–8.
65. Postolow F, Fediuk J, Nolette N, et al. Hypoxia and nitric oxide exposure promote apoptotic signaling in contractile pulmonary arterial smooth muscle but not in pulmonary epithelium. Pediatr Pulmonol. 2011; 46: 1194–208.
66. Nathan SD, Hassoun PM. Pulmonary hypertension due to lung disease and/or hypoxia. Clin Chest Med. 2013; 34: 695–705.
67. McIlhenny S, Zhang P, Tulenko T, et al. eNOS transfection of adipose-derived stem cells yields bioactive nitric oxide production and improved results in vascular tissue engineering. J Tissue Eng Regen Med. 2015; 9: 1277–85.
68. D'Souza FM, Sparks RL, Chen H, et al. Mechanism of eNOS gene transfer inhibition of vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol. 2003; 284: C191–9.
69. Kullo IJ, Schwartz RS, Pompili VJ, et al. Expression and function of recombinant endothelial NO synthase in coronary artery smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997; 17: 2405–12.